CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology as the exclusive specialty pharmacy provider for PORTRAZZA™ (necitumumab).
In addition to accessing the drug via specialty distribution, Eli Lilly will offer physicians and healthcare practices the opportunity to order PORTRAZZA™ through Biologics’ specialty pharmacy as an alternative option.
PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. It was approved by the U.S. Food and Drug Administration on November 24, 2015.
Biologics takes a high-touch approach to patient care, providing patient-specific support and individualized care plans for each patient to help manage side effects and foster adherence.
The team also works to navigate financial barriers to care by providing benefits investigation, prior authorization and copay assistance services. In 2014, the team helped secure over $29M in copay assistance for eligible patients.
Physicians may submit prescriptions to Biologics via phone (800.850.4306, option 2), fax (800.823.4506) or eScribe.
Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.
Biologics is part of McKesson Life Sciences (formerly McKesson Specialty Health), a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.